Proteostasis Therapeutics, Inc is a biotechnology business based in the US. Proteostasis Therapeutics shares (PTI) are listed on the NASDAQ and all prices are listed in US Dollars. Proteostasis Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Proteostasis Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PTI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Proteostasis Therapeutics stock price (NASDAQ: PTI)Use our graph to track the performance of PTI stocks over time.
Proteostasis Therapeutics shares at a glance
|52-week range||$18.77 - $36.80|
|50-day moving average||$2.64|
|200-day moving average||$1.40|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.50|
Buy Proteostasis Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Proteostasis Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Proteostasis Therapeutics financials
|Gross profit TTM||$5 million|
|Return on assets TTM||-31.16%|
|Return on equity TTM||-72.38%|
|Market capitalisation||$2.9 million|
TTM: trailing 12 months
Shorting Proteostasis Therapeutics shares
There are currently 1.1 million Proteostasis Therapeutics shares held short by investors – that's known as Proteostasis Therapeutics's "short interest". This figure is 16.4% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Proteostasis Therapeutics shares can be evaluated.
Proteostasis Therapeutics's "short interest ratio" (SIR)
Proteostasis Therapeutics's "short interest ratio" (SIR) is the quantity of Proteostasis Therapeutics shares currently shorted divided by the average quantity of Proteostasis Therapeutics shares traded daily (recently around 424989.88326848). Proteostasis Therapeutics's SIR currently stands at 2.57. In other words for every 100,000 Proteostasis Therapeutics shares traded daily on the market, roughly 2570 shares are currently held short.
However Proteostasis Therapeutics's short interest can also be evaluated against the total number of Proteostasis Therapeutics shares, or, against the total number of tradable Proteostasis Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Proteostasis Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Proteostasis Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0212% of the tradable shares (for every 100,000 tradable Proteostasis Therapeutics shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Proteostasis Therapeutics.
Find out more about how you can short Proteostasis Therapeutics stock.
Proteostasis Therapeutics share dividends
We're not expecting Proteostasis Therapeutics to pay a dividend over the next 12 months.
Have Proteostasis Therapeutics's shares ever split?
Proteostasis Therapeutics's shares were split on a 1:20 basis on 22 December 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Proteostasis Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Proteostasis Therapeutics shares which in turn could have impacted Proteostasis Therapeutics's share price.
Proteostasis Therapeutics share price volatility
Over the last 12 months, Proteostasis Therapeutics's shares have ranged in value from as little as $18.768 up to $36.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteostasis Therapeutics's is 1.1167. This would suggest that Proteostasis Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Proteostasis Therapeutics overview
Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc.
Proteostasis Therapeutics in the news
Frequently asked questionsWhat percentage of Proteostasis Therapeutics is owned by insiders or institutions?
Currently 15.299% of Proteostasis Therapeutics shares are held by insiders and 22.571% by institutions. How many people work for Proteostasis Therapeutics?
Latest data suggests 44 work at Proteostasis Therapeutics. When does the fiscal year end for Proteostasis Therapeutics?
Proteostasis Therapeutics's fiscal year ends in December. Where is Proteostasis Therapeutics based?
Proteostasis Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135 What is Proteostasis Therapeutics's ISIN number?
Proteostasis Therapeutics's international securities identification number is: US74373B1098 What is Proteostasis Therapeutics's CUSIP number?
Proteostasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74373B109
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert